'Ifn' presentation slideshows

B?C??????????????

B?C??????????????. ?????????? ?????? ??? ?????. ??????????? ????. ? ? ? ? ~. ??????. ?? ~ ??? ~ ??????? ~ ??????? ~ ?? ~ ???? ~. ???? BC ??????? ?????????? ~. ???? ???????? ?????? ?????????? ?? ???? ??????? ??????? ???????. ????. ???? ???????? ?????? ?????????? ?? ????

2.68k views • 94 slides

Chapter 8 The interferon family

Pharmaceutical Biotechnology. Chapter 8 The interferon family. Dr. Tarek El-Bashiti Assoc. Prof. of Biotechnology. Cytokines. Cytokines are a diverse group of regulatory proteins or glycoproteins whose classification remains somewhat diffuse (Table 8.1).

803 views • 68 slides

618 views • 46 slides

Pius-Hospital Oldenburg

703 views • 39 slides

Combination Therapy of Chronic Hepatitis Delta

Combination Therapy of Chronic Hepatitis Delta. Ulus Salih Akarca Ege University, Faculty of Medicine Izmir, Turkey. The logic of the combination treatment of chronic hepatitis delta. Chronicity. Lower effect of immune modulator treatments. Escape from immune system.

524 views • 32 slides

New Anti-HCV Drugs Other Drugs?

559 views • 27 slides

CYTOKINES- ITS PROPERTIES AND FUNCTION

CYTOKINES- ITS PROPERTIES AND FUNCTION. BY- CHANDANA KALITA MSC BIOTECHNOLOGY 2 nd SEM ROLL NO. 03 GAUHATI UNIVERSITY. CYTOKINES.

927 views • 25 slides

Harro Frauendorf

Harro Frauendorf. Introduction. Infection: microbes vs. host Viruses try to secure a niche for replication Host must limit pathogen's advance Type 1 interferons are key players many members: IFN- ? / ? Virus evolved tricks to avoid antiviral effects of IFNs (co evolution).

437 views • 24 slides

Jorge R. Oksenberg, Ph.D. Professor of Neurology University of California, San Francisco

372 views • 24 slides

Adjuvant Therapy for Melanoma What is the role of PegIFN in relation to HDIFN?

Adjuvant Therapy for Melanoma What is the role of PegIFN in relation to HDIFN?. John M. Kirkwood, MD Professor of Medicine, Dermatology and Translational Science University of Pittsburgh School of Medicine &Cancer Institute Melanoma Committee, Eastern Cooperative Oncology Group

370 views • 19 slides

Chapter 8 The interferon family

Pharmaceutical Biotechnology. Chapter 8 The interferon family. Dr. Tarek El-Bashiti Assoc. Prof. of Biotechnology. Cytokines. Cytokines are a diverse group of regulatory proteins or glycoproteins whose classification remains somewhat diffuse (Table 8.1).

390 views • 19 slides

Analysis of anti-TNF-induced skin lesions reveals strong Th1 activation with some distinct immunological characteristics.

479 views • 12 slides

FSC

pDC. medium. Flu. CL097. 20 %. 85 %. 95 %. CD40. BDCA2. CD123. FSC. GEN2.2 cells. medium. Flu. CL097. 25 %. 82 %. 97 %. CD40. SSC. FSC. FSC. 100. GEN2.2. 2.5. GENshTLR7. GEN2.2. 80. GENshTLR7. 2.0. 60. % CD40 positive cells. 1.5. relative Ct. 40. 1.0. 20. 0.5.

268 views • 6 slides

Sup. Fig. 2

IFN- g (pg/ml). C-REP. T-REP. MART-1 peptide ( m M). C-REP. T-REP. 18 6 2 0.67 0.22. E:T ratio. A. B. IFN- g (pg/ml). 0.5. 0. 0.1. 1. TGF- b ( ng/ml ). C. Sup. Fig. 2. 1.8. 4.2. Mart-1. CD8. CD107a. 44.2. 37.8. Mart-1. CD8.

124 views • 3 slides

SEM and TEM images of BCNTs grown by SSP?LPP.

Design and manufacturing of large area, thick cBN films Peter X. Feng (University of Puerto Rico), DMR 0706147.

242 views • 2 slides

tnf- a (fold change)

Figure S1. D. A. IL-12 (pg/ml). il-12 (fold change). Cytokine (pg/ml). mRNA levels. B. E. IFN g (pg/ml). ifn- g (fold change). Donor 1. Donor 1. Donor 1. Donor 1. Donor 1. Donor 1. Cytokine (pg/ml). Donor 2. Donor 2. Donor 2. Donor 2. Donor 2. Donor 2. mRNA levels. C.

147 views • 2 slides

IL-17

IL-17. MIF. MMP. IL-18. T1, 2. IFN - g. IL-2. Angiogenesis VEGF, FGF, HGF IL-8, angipoietin-1 Stromal cell derived GF TNF, TGF (indirect). Angiostatic IL-12, IFN -a b g, PF4. Adhesion molecules ICAM-1,2 VAM-1 *b -i ntegrin LAF-3 *P-selectin. BMP MIF. IL-17. IL-15. TNF - a

193 views • 2 slides

IL-10 IL-12 TNF a TNF b

Macrophage. Neutrophil. B-Cell. Eosinophil. Basophil. T-Cell. Mast Cell. IFN a IFN b IFN g. IL-1 IL-6 IL-10 IL-12 IL-15 TNF a. IL-1 IL-8 TNF a. IL-10 IL-12 TNF a TNF b. IL-1 IFN a IFN b TNF a TNF b. IL-1 IFN a IL-6 IFN g IL-8 IFN a IL-10 IL-12 IL-15 IL-18. TNF a. IL-1 IL-8.

161 views • 1 slides

SKRC-1

None. IFN- b. SKRC-1. R1: 0.6 R2: 44.0 R3: 44.2 R4: 10.5. R1: 0.5 R2: 50.4 R3: 33.7 R4: 14.9. R1: subG1 R2: G0/G1 R3: S R4: G2/M. Anti- BrdU -FITC. SKRC-44. R1: 3.7 R2: 33.1 R3: 43.2 R4: 13.2. R1: 2.0 R2: 44.1 R3: 29.0 R4: 18.4. R3. R2. R4. R1. 7AAD.

216 views • 1 slides

PLSCR1

Figure S2. A. SnoN mRNA Levels. 1h IFN-2 ?. Untreated. 3h IFN-2 ?. C. B. HEY: IFN-2 ?. HEY: IFN - 2?. Control siRNA. SnoN siRNA. 6h. 6h. IFN+NAC (1000). 0h. 0h. IFN+NAC (100). IFN+NAC (500). NAC (1000). IFN only. None. 38 kDa. PLSCR1. 31 kDa. 38 kDa. PLSCR1.

176 views • 1 slides